Introduction {#s1}
============

Osteoarthritis (OA) is the most common form of arthritis affecting 40% of people over the age of 70 years and is one of the most common disabling diseases observed worldwide.[@R1] [@R2] Its aetiology is multifactorial with a clear genetic component. Inheritance studies in twins and other family-based studies have assessed the estimated heritability for OA in the range of 40--65% depending on the joint site.[@R3] The established OA loci have small ORs (range 1.10--1.20)[@R6] [@R7] and the genetic architecture of OA is likely to consist of multiple variants of similar magnitude.

During the last few years, extensive efforts have led to the identification of a number of OA susceptibility signals in European populations that have surpassed the genome-wide significance (GWS) level (p\<5×10^−8^). A locus on chr7q22 near the orphan receptor *GPR22* derived from genome-wide association studies (GWAS)[@R8] [@R9] and a variant in the *GDF5* gene, originating from a candidate gene approach reached GWS for knee OA.[@R10] An analysis using a 1000-genomes-project-based imputations identified a variant on chromosome 13q34 near the *MCF2L* gene.[@R7] A recent GWAS in UK subjects revealed eight more loci that increase risk for OA. From those eight loci, four signals in 9q33 (*ASTN2*), 6q14 (*FILIP1*/*SENP6*), 12p11 (*KLHDC5/PTHLH*) and 12q23 (*CHST11*) were found to be associated with total hip replacement (THR) or hip OA in European populations.[@R6] Finally, GWAS and functional studies revealed that the *DOT1L* gene on 19q13 is also associated with hip OA and cartilage thickness.[@R11] [@R12]

In this study a large-scale GWAS meta-analysis for hip OA was performed under the auspices of the Translational Research in Europe Applied Technologies in Osteoarthritis (TreatOA) consortium including eight sample sets, in the discovery stage. With a total of 4349 hip OA cases and 46 903 controls in the discovery stage, and a total of 11 277 cases and 67 473 controls, this is the largest study of hip OA to date.

Methods {#s2}
=======

Study design and analysis plan {#s2a}
------------------------------

A two-stage design was used for the identification of potential associations. In the discovery stage imputed and directly genotyped autosomal single nucleotide polymorphism (SNPs) were assessed using a quality control (QC) procedure that is described in the online supplementary material (section 1.a). Briefly, we excluded SNPs based on low minor allele frequency (MAF \<1%), low imputation quality, low call rate and deviation from the Hardy-Weinberg equilibrium. Genomic control was applied to each study before meta-analysis. The effect estimates of each study where synthesised using an additive model. The variants that surpassed the p\<1×10^−6^ threshold in the meta-analysis were selected for further follow-up. Besides the main analysis including all participants a separate analysis stratified by sex was performed to detect possible sex-specific signals. In silico and de novo replication was sought for the discovery signals in 10 additional studies. All the derived effects from the discovery and the replication stage were finally synthesised using inverse variance fixed-effect models and the between-study heterogeneity was assessed using the I^2^metric.[@R13] Moreover, a random-effects (RE) model was applied.[@R14] A p-value of \<5×10^−8^ was considered GWS. The associations of the top findings at the discovery stage were also assessed when adjusted for other risk factors such as age, height and body mass index (BMI). We also examined the association of these markers with height and BMI in the large publicly available sample set of the Genetic Investigation of Anthropometric Traits (GIANT) consortium (133 000 individuals in height analysis and 123 000 individuals in BMI analysis.[@R15] [@R16] The detailed analysis plan is presented in the online supplementary material (section 1.b).

Study populations and phenotype definition {#s2b}
------------------------------------------

The studies included in the discovery and replication efforts are described in [table 1](#ANNRHEUMDIS2012203114TB1){ref-type="table"} and more details are given in the online [supplementary material](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1) (section 1.c). All studies had standardised definitions of the phenotypes. Specifically, the definition of the hip OA in the studies was either a radiographic Kellgren and Lawrence (K/L) grade of ≥2 or history of a THR surgery because of OA. THR subjects were excluded from the study if they had: other major arthropathy (eg, rheumatoid arthritis, ankylosing spondylitis); Paget\'s disease affecting the pelvis or femur; THR due to hip trauma or avascular necrosis of the femoral head; or terminal illness. The control groups consisted of subjects who had no known affected joints. Population-based controls were used by the arcOGEN study.

###### 

Studies included in the TreatOA GWAS meta-analysis

  Study                N cases   N controls   λ        N SNPs      ROA/SOA   Controls              Genotyping platform                                                                          Imputation method
  -------------------- --------- ------------ -------- ----------- --------- --------------------- -------------------------------------------------------------------------------------------- -------------------
  Discovery stage                                                                                                                                                                               
   arcOGEN stage 1     1728      4896         1.058    2.454.242   ROA/SOA   Population            Illumina Human610 (cases)+Illumina 1.2M Duo (controls)                                       Impute
   deCODE              1423      31 385       1.182    2.399.690   SOA       Osteoarthritis-free   Infinium HumanHap 300+humanCNV370                                                            Impute
   EGCUT               64        2531         0.994    2.242.156   ROA       Population            Illumina HumanCNV370 or HumanOmniExpress                                                     Impute
   GARP                106       1671         1.294    2.406.007   SOA/ROA   KL\<2                 Illumina Infinium HD Human660W-Quad                                                          Impute
   RSI                 760       3233         1.009    2.450.385   ROA       KL\<2                 Illumina HumanHap550v3                                                                       MACH
   RSII                159       1472         0.993    2.442.419   ROA       KL\<2                 Illumina HumanHap550-Duo                                                                     MACH
   RSIII               41        1487         0.962    2.397.764   ROA       KL\<2                 Illumina Human660W-Quad                                                                      MACH
   TwinsUK             68        228          0.993    2.358151    ROA       KL\<2                 Infinium HumanHap300                                                                         Impute
  Total discovery      4349      46 903       1.028    2.567.279                                   --                                                                                           --
  Replication stage                                                                                                                                                                             
   arcOGEN stage 2     1763      6157         1.058    --          ROA/SOA   --                    Illumina Human610 (cases)+Illumina 1.2M Duo (controls)                                       Impute
   SOF\*               761       2376         1.008    --          ROA       --                    Illumina Omni 1 array (1.1 million probes)                                                   MACH
   MrOS\*              446       2837         1.002    **--**      ROA       --                    Illumina Omni 1 array (1.1 million probes)                                                   MACH
   arcOGEN plus        223       1828         **--**   --          ROA/SOA   --                    Illumina Human610 (cases)+Illumina 1.2M Duo (controls)                                       Impute
   EGCUT               977       1131         **--**   --          ROA       --                    Illumina HumanCNV370 or HumanOmniExpress                                                     Impute
   Greek TJR cases     93        361          **--**   --          SOA       --                    Single base extension using SNaPshot Multiplex Kit (Applied Biosystems, Foster City, USA))   --
   Paprika Study       602       2321         **--**   --          SOA       --                    Sequenom (MassARRAY iPLEX Gold)                                                              --
   Spanish TJR cases   697       783          **--**   --          SOA       --                    Single base extension using SNaPshot Multiplex Kit (Applied Biosystems, Foster City, USA))   --
   Icelandic cases     857       1857         **--**   --          SOA       --                    Centaurus (Nanogen)[@R37]                                                                    
   Swedish MDC study   509       919          **--**   --          SOA       --                    Centaurus (Nanogen)[@R37]                                                                    --
  Total replication    6928      20 570                                                            --                                                                                           --
  Total                11 277    67 473                                                            --                                                                                           --

EGCUT, Estonian Genome Center, University of Tartu; GWAS, genome-wide association studies; HD, high density; KL, Kellgren-Lawrence score; MDC, Malmo Diet Cancer study; MrOS, Osteroporotic Fractures in Men study; ROA, radiographic osteoarthritis; SOA, symptomatic osteoarthritis; SOF, Study of Osteoporotic Fractures; TJR, total joint replacement.

Genotyping and imputation {#s2c}
-------------------------

Genotyping of GWAS genotyping was performed by each study following standard protocols and imputation was then carried out at the individual study level on the ∼2.5 million SNPs from HapMap Phase 2 release 22 using genome build 36 (Utah residents with ancestry from northern and western Europe (CEPH))[@R17] on MACH or IMPUTE[@R18] software. Imputation quality scores for each SNP were obtained from IMPUTE and MACH statistics, as appropriate. An overview of all studies and the genotyping platforms and imputation method used is given in [table 1](#ANNRHEUMDIS2012203114TB1){ref-type="table"}. Ten studies of European ancestral origin provided data for independent replication. Four datasets (arcOGEN stage 2, arcOGEN plus, Osteroporotic Fractures in Men study and the Study of Osteoporotic Fractures) provided 'in silico' replication whereas 'de novo' replication was performed in six other study groups (Icelandic, Swedish, Estonian Genome Center, University of Tartu (EGCUT), Paprika study, Greek, Spanish). QC criteria for deviation from Hardy-Weinberg equilibrium, MAF inconsistencies with the discovery data and outliers were applied in the replication data before including all the available data in the final analysis.

Gene expression {#s2d}
---------------

Expression was determined by Illumina HT-12 V3 microarrays using standard methods using 47 000 probes corresponding to over 25 000 well-characterised genes. DNA was available from blood and cartilage. Using the Beadstudio software the intensity values were normalised using the 'rsn' option in the Lumi R-package. The corresponding signals increase exponentially with relative levels and units are light intensity (Illumina provided values). The obtained raw probe-level data (overall mean normalised probe level value of measured genes in cartilage) were exported for analyses using Limma.[@R19] As implemented in Limma, a paired t test was used on all samples. There were two probes, approximately 2.2 kb apart, on the array used for *NCOA3*.

Heritability of hip OA explained by genetic variants {#s2e}
----------------------------------------------------

We calculated the sibling recurrence risk and the expected genetic variance explained for hip OA hits that were identified previously and in this study as described in online [supplementary material](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1) (section 1.e)

Results {#s3}
=======

The final analysis included a total of 11 277 radiographic and symptomatic hip OA cases and 67 473 controls of European ancestry, with 4349 cases and 46 903 controls included in the discovery stage and 6928 cases and 20 570 controls in the follow-up effort ([table 1](#ANNRHEUMDIS2012203114TB1){ref-type="table"}). In the sex-specific analyses 2045/20 823 male cases and controls and 2689/25 384 female cases and controls were analysed in the discovery. After QC, 2 567 279 SNPs were analysed. Low genomic inflation factor was observed for the first stage with λ=1.028. The results of the discovery stage were uncorrected for the overall inflation factor. Quantile-Quantile plots showed an excess of signals compared with what was expected by chance, indicating the presence of true association signals that could confer susceptibility to hip OA (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1)s S1--S3). For male-specific analysis (see online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1) S3) there is an early deviation from the neutrality line, therefore positive signals should be treated with caution.

Following analysis of the discovery stage it was found that eight independent loci reached the prespecified threshold of p\<1.0×10^−6^ required for further replication; five from the combined analysis of sexes, two male-specific and one female-specific loci. The number of independent SNPs is larger compared with three estimated independent SNPs expected under the null for the main and the sex-specific analyses (binomial test p=0.012). Two of these signals (rs6094710 at 20q13 and rs640070 at 11q25) were imputed, had MAF \<5% and moderate or large effect sizes were observed (OR \>1.2). Therefore, we examined for possible imputation errors by comparing with de novo genotyping in a random sample of the RS-I and the Twins UK studies to exclude any chance of false positive findings. The obtained MAF estimates between the imputation and the genotyping efforts were not consistent for rs640070, which was therefore excluded from further consideration, minimising the chance of any false positive signals (see online [supplementary material](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1); section 1.d). Moreover, we included in the replication stage rs17610181 at 17q23, a SNP that was just below the desired threshold, but was previously shown to be associated with height.[@R15] Therefore, eight independent SNPs were included in the replication phase. The combined effect sizes and p values for the eight signals are presented in [table 2](#ANNRHEUMDIS2012203114TB2){ref-type="table"} and in online [supplementary figure](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1)s S4--S11. None of these variants associate with height or BMI in the large publicly available GIANT databases (see online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1) S2) nor did including these covariates, or age, in the analysis change the association of OA with these genetic variants (see online [supplementary table](http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2012-203114/-/DC1) S3).

###### 

Association results for hip OA meta-analysis of the discovery and the replication studies

  SNP                                  Chr     Gene     A1   EAF (%)   Discovery stage       Replication stage   Combined                                                                              
  ------------------------------------ ------- -------- ---- --------- --------------------- ------------------- ---------- --------------------- ------------ --------------------- ------------ ---- -------------
  Combined analysis of both genders:                                                                                                                                                                   
   rs6094710                           20q13   NCOA3    A    4         1.40 (1.24 to 1.58)   5.6×10^−8^          0          1.20 (1.08 to 1.34)   7.3×10^−4^   1.28 (1.18 to 1.39)   7.9×10^−9^   64   2.0×10^−10^
   rs1577792                           6q14    HMGN3    A    39        1.14 (1.09 to 1.20)   7.3×10^−8^          0          1.03 (0.99 to 1.07)   0.17         1.07 (1.04 to 1.11)   7.8×10^−5^   50   9.6×10^−6^
   rs5009270                           7q31    IFRD1    A    30        1.15 (1.09 to 1.21)   5.7×10^−7^          21         1.05 (1.00 to 1.11)   0.061        1.10 (1.06 to 1.14)   9.0×10^−7^   46   3.1×10^−6^
   rs10773046                          12q24   DNAH10   G    45        1.13 (1.08 to 1.19)   9.7×10^−7^          10         1.01 (0.96 to 1.06)   0.72         1.07 (1.03 to 1.11)   2.0×10^−4^   64   1.9×10^−6^
   rs17610181                          17q23   NACA2    A    14        1.20 (1.11 to 1.29)   1.9×10^−6^          32         1.05 (0.99 to 1.12    0.12         1.12 (1.06 to 1.18)   1.3×10^−5^   42   7.5×10^−6^
  Female-specific analysis:                                                                                                                                                                            
   rs10878630                          12q15   DYRK2    A    41        1.19 (1.11 to 1.26)   1.2×10^−7^          25         0.98 (0.91 to 1.05)   0.52         1.09 (1.04 to 1.14)   3.9×10^−4^   65   1.1×10^−5^
  Male-specific analysis:                                                                                                                                                                              
   rs12551314                          9q22    PHF2     A    12        1.30 (1.18 to 1.44)   6.3×10^−7^          28         0.98 (0.86 to 1.11)   0.72         1.16 (1.07 to 1.25)   2.9×10^−4^   66   4.3×10^−5^
   rs3757837                           7p13    CAMK2B   C    6         1.46 (1.26 to 1.69)   8.3×10^−7^          46         1.15 (1.00 to 1.32)   0.044        1.27 (1.15 to 1.41)   2.2×10^−6^   78   7.7×10^−10^

The discovery sample set comprised 4349 hip OA cases and 46 903 controls, and the replication samples were 6928 cases and 20 570 controls in the analysis of both genders. The female-specific analysis comprised 2689 hip OA cases and 25 384 controls in the discovery set and 2398 cases and 8787 controls in the replication stage. For the male-specific analysis there were 2045 hip OA cases and 20 823 controls in the discovery set and 1386/7087 and 1451/4956 cases/controls in the replication stage for rs12551314 and rs3757837 respectively.

A1, coded/effect allele; Chr, chromosome; EAF, effect allele frequency; Gene, nearest gene; HE RE P, Han & Eskin Random Effects P; I^2^, measure of heterogeneity; OA, osteoarthritis.

Two SNPs, rs6094710 at 20q13 and rs1577792 at 6q14, were borderline GWS in the discovery stage with p=5.8×10^−8^ and 7.3×10^−8^, respectively, with no observed heterogeneity (I^2^=0). The SNP rs6094710 replicated with p=7.3×10^−4^ in the follow-up samples and reached GWS level with p=9.3×10^−9^ and OR=1.28 (95% CI 1.17 to 1.39) when we combined the discovery and the replication data, although large heterogeneity was observed I^2^=64% ([figure 1](#ANNRHEUMDIS2012203114F1){ref-type="fig"}). The SNP remained GWS after the second genomic control. rs6094710 is annotated near *NCOA3* (nuclear receptor coactivator 3) gene. The OR of rs1577792 at 6q14 was close to unity in the replication effort with one study being significant in the opposite direction.

![(A) Forest plot for meta-analysis of rs6094710. The blue diamond in the forest plot denotes the summary effect size and its edges the respective 95% CIs. Studies shaded in blue were included in the replication stage. \*Discovery and replication estimate combined; and (B) regional plot for rs6094710 comprising directly genotyped and imputed SNPs. Case-control association results (−log10 P) in the discovery set are plotted against genomic position (National Center for Biotechnology Information build 36) for the stratum where the most significant meta-analysis p was observed. The colour reflects the correlation coefficients (r^2^) of each genotyped SNP with the index SNP estimated using the CEU HapMap II panel.](annrheumdis-2012-203114f01){#ANNRHEUMDIS2012203114F1}

The rs3757837 SNP at 7p13 from the male-specific analysis replicated nominally (p=0.044, OR=1.15) in the follow-up samples, but did not reach GWS in the overall analysis with p=2.2×10^−6^ and OR=1.27. Moderate heterogeneity was observed for this SNP in the discovery analysis (I^2^=46%). Heterogeneity was increased, in the overall analysis with all the studies combined (I^2^=78%), reflecting the further heterogeneity introduced by the replication data. We, therefore, also applied the Han and Eskin (RE) model, an approach that allows more heterogeneity in the data compared with traditional models.[@R14] Using this model rs3757837 showed a stronger association with p=7.7×10^−10^ in this analysis. The strength of the association of this approach was not substantially different from the fixed-effect model for any other SNP in our study ([table 2](#ANNRHEUMDIS2012203114TB2){ref-type="table"}). rs3757837 resides in intron 8 of the *CAMK2B* (calcium/calmodulin-dependent protein kinase II β) gene.

The rs5009270 SNP at 7q31 remained suggestively associated in the final analysis (p\<5×10^−6^) with combined two-stage p=9.9×10^−7^ and summary OR 1.10. rs5009270 is located near the *IFRD1* (interferon-related) gene. The p with the RE approach was 3.1×10^−6^.

Gene expression data {#s3a}
--------------------

To further investigate our findings for the top GWS hit at 20q13 we explored mRNA expression profile of the *NCOA3* gene in articular cartilage, a highly relevant tissue for OA. Expression of the gene was examined by exploring a micro array mRNA expression dataset generated on Illumina V3 Human-12 chips in cartilage samples of 33 patients (13 men and 20 women of European descent aged 54 years to 80 years) that underwent joint replacement due to end-stage OA disease. Expression levels of *NCOA3* in cartilage displaying symptoms of OA were compared with expression levels in cartilage that appeared macroscopically normal but isolated from the same joint (preserved cartilage). A moderate level of expression, as determined by the mean normalised probe level value, was observed for *NCOA3* (mean level 8.49), which was above the observed average expression of genes in the articular cartilage (mean normalised probe level value of measured genes in cartilage was 7.4; range 6.6--14.9). Expression was also high in blood (6.96; range 6.3--14.7). When we tested for differential expression of *NCOA3* among the pairs of preserved and OA-affected cartilage, we observed a significantly lower expression of *NCOA3* in the OA-affected cartilage (p=0.0064).

Heritability of hip OA explained by genetic variants {#s3b}
----------------------------------------------------

[Table 3](#ANNRHEUMDIS2012203114TB3){ref-type="table"} summarises genome-wide significant and suggestive signals of hip OA including this study. Based on these findings and if we consider a sibling recurrence ratio λ~s~=5[@R20] then the discovered signals of OA contribute 3% of the heritability in OA when all hits are considered and 2.1% if only GWS are evaluated.

###### 

Summary of the genome-wide significant and suggestive SNPs for hip OA and their estimated heritability

  Reference                                        SNP          Gene             OR     EAF    λ~s~     Expected GV explained (%)
  ------------------------------------------------ ------------ ---------------- ------ ------ -------- ---------------------------
  Genome wide significant findings (p\<5×10^−8^)   * *                                                  
   This study                                      rs6094710    *NCOA3*          1.28   0.04   1.0029   0.46
   arcOGEN[@R6]                                    rs6976       *GLT8D1*         1.12   0.37   1.0031   0.60
   arcOGEN[@R6]                                    rs11177      *GNL3*           1.12   0.38   1.0031   0.60
   arcOGEN[@R6]                                    rs4836732    *ASTN2*          1.20   0.47   1.0083   1.66
   arcOGEN[@R6]                                    rs9350591    *FILIP1;SENP6*   1.18   0.11   1.0030   0.54
   arcOGEN[@R6]                                    rs10492367   *KLHDC5;PTHLH*   1.14   0.19   1.0029   0.53
   3arcOGEN[@R6]                                   rs835487     *CHST11*         1.13   0.34   1.0034   0.67
   TreatOA[@R12]                                   rs12982744   *DOT1L*          1.17   0.38   1.0060   1.16
  Suggestive findings (5×10^−6^\<p\<5×10^−8^)      * *                                                  
   This study                                      rs5009270    *IFRD1*          1.10   0.30   1.0019   0.38
   This study                                      rs3757837    *CAMK2B*         1.27   0.06   1.0040   0.64
   arcOGEN[@R6]                                    rs12107036   *TP63*           1.21   0.52   1.0090   1.81
   arcOGEN[@R6]                                    rs8044769    *FTO*            1.11   0.50   1.0027   0.54
   arcOGEN[@R6]                                    rs10948172   *SUPT3H;CDC5L*   1.14   0.29   1.0037   0.71

EAF, effect allele frequency; GV, genetic variance; OA, osteoarthritis.

Discussion {#s4}
==========

In this report we attempted to further clarify the genetic architecture of the genetic background of hip OA by using the largest sample-size for hip OA to-date of more than 78 000 genotyped individuals under a GWAS framework. During the discovery phase, we identified eight signals that qualified for further independent replication. Of these, the signal at chromosome 20q13 near *NCOA3* gene was found to be GWS and two other loci were suggestively significant at a p\<5×10^−6^ level in the joint analysis of the discovery and replication stages. Adjusted analyses of the prioritised signals revealed that these markers were not associated with body size. These genetic risk factors contribute to our knowledge base in the field of the susceptibility for hip OA by conferring a medium OA risk.

The top signal identified in this meta-analysis was rs6094710, a variant that is annotated on chromosome 20q13 near the *NCOA3* gene, increasing the risk for hip OA for the carriers of the A allele by almost 30%. Furthermore, we showed that the identified *NCOA3* gene was expressed in articular cartilage and its expression was significantly reduced in OA affected cartilage, further supporting a role of the *NCOA3* gene signal in OA disease process. Interestingly, rs6094710 is in complete linkage disequilibrium with rs6094752 (r^2^=1) which is a missense SNP leading to an amino acid change at position 218 in the protein (Arg\>Cys). This amino acid change is predicted to have a benign and damaging effect on the protein by PolyPhen-2,[@R21] dependent on the variant protein. The functional consequences of SNP rs6094752 are unknown, and further research is therefore needed to unravel the biological mechanism of this amino acid change in relation to OA.

The *NCOA3* gene is a nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. In this signalling process, *NCOA3* recruits histone acetyltransferases and methyltransferases for chromatin remodelling and facilitating downstream gene transcription. *NCOA3* is involved in the coactivation of different nuclear receptors, such as for steroids, retinoids, thyroid hormone, vitamin D3 and prostanoids. Many of these hormones have been implicated in skeletal metabolism and OA, which makes *NCOA3* a compelling causal candidate gene. Previously, *NCOA3* knockout mice were generated through homologous recombination in embryonic stem cells.[@R22] These mice showed growth retardation and reduced adult body size, but the molecular mechanism responsible for this growth retardation remains largely unknown. In addition, female mice exhibited abnormal development and function of their reproductive system and oestrogen levels were significantly lower in the knockout mice compared with the wild type,[@R22] possibly indicating involvement of NCOA3 in steroid regulation.

*NCOA3* could be also implicated through regulation of the target tissue responses to thyroid hormone (T3).[@R23] Since intracellular T3 is tightly regulated by deiodinase, iodothyronine, type-2 and deiodinase, iodothyronine, type-3 encoded by the *DIO2* and *DIO3* genes, respectively, that were previously recognised as OA susceptibility genes,[@R24] [@R25] the current *NCOA3* findings complement the previous outlined hypothesis that local T3 signalling may affect OA susceptibility.[@R26]

Another possible mechanism by which NCOA3 might be involved in cartilage homoeostasis is through transcriptional regulation in mechanotransduction. *NCOA3* is upregulated by the signal transducer and activator of transcription 6 (STAT6) in naïve splenic B cells from BALB/c and serves as a positive regulator of transcriptional activation by STAT6.[@R27] STAT6 is known to be the common signal transducer of interleukin (IL)-4 receptor α chain and mediates IL-4- and IL-13-induced responses.[@R28] Chondrocytes from normal and OA cartilage signal through a type II IL-4R in in human articular chondrocyte mechanotransduction. This signalling is via a STAT6-independent pathway. Differences in IL-4 signalling are likely due to crosstalk between integrin and cytokine signalling pathways.[@R29] Therefore, *NCOA3* may be related to cartilage function and molecular signalling and transcriptional regulation in mechanotransduction.

The male-specific locus on 7p13, represented by rs3757837, showed considerable heterogeneity between studies. The signal was strongly supported by the RE model. Unlike the conservative traditional RE methods this new method has been shown to achieve higher statistical power when heterogeneity exists, allowing for new discoveries in the field of genetic epidemiology.[@R14] rs3757837 is located in *CAMK2B* gene, which belongs to the calcium/calmodulin-regulated kinase (CaMKII) subfamily. There is evidence that CaMKII-signalling may be important in onset and progression of OA.[@R30] [@R31] This pathway has been described as central to the molecular events that regulate chondrocyte responses to mechanical stimulation and in particular, to the upstream effect of IL-4*.* This would be linked to the STAT6 pathway, which in turn is regulated by *NCOA3*. Thus these two genetic signals, *NCOA3* and *CAMK2B*, both point to pathways related to cartilage mechanotransduction, suggesting that genetic defects in this pathway may be central to the degeneration of cartilage that takes place in hip OA. OA is a disease affecting articular cartilage and the underlying bone, resulting from many biological and mechanical interacting factors which change the extracellular matrix and cells and lead to increasing levels of cartilage degeneration. Joint tissues are exquisitely sensitive to their mechanical environment, and mechanical loading may be the most important external factor regulating the development and long-term maintenance of joint tissues.[@R32] Finally, rs5009270 resides near *IFDRD1* which codes an interferon-related developmental regulator and has been implicated in skeletal muscle regeneration.[@R33] Reduction in muscle strength is strongly associated with functional decline, and individuals with lower quadriceps strength adjusted for body weight are more likely to develop OA.[@R34]

Our study has certain limitations. In our discovery stage, two out of the eight independent loci had no heterogeneity and in five signals the heterogeneity was moderate or low. However, when we included the replication data, large heterogeneity was introduced for all SNPs. Conflicting results in the replication data, besides chance, could be explained by inconsistent definitions of the OA phenotypes but also from the different population structure that can introduce heterogeneity. The TreatOA consortium has addressed the need of standardisation of OA phenotypes[@R35] and this effort may have diminished the observed heterogeneity in the discovery stage. Efforts including more data using common and stringent QC criteria and standardisation methods should substantially improve the power of GWAS to identify novel findings in the near future. The main limitation of the expression study is that there are few individuals included, in particular only two carriers of the rs6094710 variant.

In conclusion, novel loci involved in hip OA were discovered through a large-scale meta-analysis of GWAS. The exact underlying mechanism leading to a higher risk of OA remains to be elucidated by functional experiments. It is evident from this work and other recent studies that deciphering the architecture of the genetics of OA requires major large-scale efforts, and in this regard calls for international worldwide collaborations are not fruitless. In the near future emphasis should be given to the enhancement of the total sample size, the adoption of stringent and standardised definitions of the phenotypes and the application of imputation-based meta-analysis using the panel of the 1000 Genomes Project.[@R36] In addition, linking results from genetic association studies to for example genome-wide RNA expression data might further improve our understanding. Eventually, large-scale studies with whole-genome sequencing will be needed to target the heritability caused by less common variants.
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